$XBI $137.3 +2.2%
Want to access our searchable Catalyst Calendar of over 1,000 biotech stock events and more? Try BiopharmIQ for 30 days free, no credit card required. Check it out here!
Covid Updates
$SRNE +10.6% Sorrento Receives EUA Approval and Import License From Mexico Authority COFEPRIS For COVI-STIX™ (COVID-19 Virus Rapid Antigen Detection Test) and Plans Product Launch With Initial Shipments in July. source
Pipeline Updates
$RCUS +15.5% On 6/23 Anti-TIGIT Domvanalimab-Based Combinations Showed Encouraging Clinical Activity in People with Metastatic, PDL1-High Non-Small Cell Lung Cancer at First Interim Analysis of Arcus Biosciences’ Randomized Phase 2 ARC-7 Study. source
$RVMD -0.5% Revolution Medicines Announces Publication of Scientific Paper Describing Novel Class of Anti-Tumor Compounds Targeting mTORC1. source
$TERN +1.9% Terns Announces Initiation of Patient Dosing in AVIATION Phase 1b NASH Clinical Trial of VAP-1 Inhibitor TERN-201. source
$EOLS -0.8% Peer Reviewed Article Highlights Efficacy and Safety of Jeuveau® in Patients with Skin of Color. source
$PRTA +1.6% Prothena Announces Bristol Myers Squibb Opt-in of Anti-Tau PRX005 as the First Program from Global Neuroscience Research and Development Collaboration. source
$KURA +3.2% Kura Oncology Doses First Patient in Phase 1b Expansion Cohorts with Menin Inhibitor KO-539. source
$SLS -3.8% SELLAS Reports Encouraging Updated Clinical Data from Ongoing Mesothelioma Study of Galinpepimut-S (GPS) Combined with Opdivo. source
$AGLE +8.0% Aeglea BioTherapeutics Doses First Patient in a Phase 1/2 Clinical Trial of AGLE-177, a Potential First-in-Class Treatment for Homocystinuria. source
$CRBP +4.0% Corbus Pharmaceuticals Announces Topline Results from DETERMINE Phase 3 Study of Lenabasum for Treatment of Dermatomyositis. source
$PTCT +1.7% Results Add to Body of Evidence Confirming EMFLAZA®'s Benefit Over Prednisone. source
$AQST -2.7% Aquestive Therapeutics Resubmits New Drug Application for Libervant™ (diazepam) Buccal Film. source
$ALPN +4.6% Alpine Immune Sciences Announces First Patient Dosed in Synergy, ALPN-101 Phase 2 Lupus Clinical Trial and $45 million in Development Milestones Achieved Under AbbVie Collaboration. source
$LGVN +4.9% Longeveron Announces Abstract Highlighting Data from Phase 1 Alzheimer’s Disease Trial Accepted for Developing Topics Presentation at the 2021 Annual Alzheimer's Association International Conference. source
$PIRS +23.5% Pieris Pharmaceuticals Receives Orphan Drug Designation for Cinrebafusp Alfa for the Treatment of Gastric Cancer. source
$VECT +1.7% VectivBio Receives FDA Orphan Drug Designation for Apraglutide for Acute Graft-Versus-Host Disease. source
$VKTX +4.4% Viking Therapeutics Announces Initiation of Phase 1b Clinical Trial of VK0214 in Patients with X-ALD. source
$AGTC +3.6% AGTC Reports 12-Month Data from its Ongoing Phase 1/2 Achromatopsia Clinical Trials Showing Biologic Activity in Patients with Mutations in the ACHM B3 Gene. source
$ARAV +5.3% Aravive Announces Positive Initial Results from Phase 1b Portion of the Phase1b/2 Study of AVB-500 in Combination with Cabozantinib in Clear Cell Renal Carcinoma. source
$FULC -4.0% Fulcrum Therapeutics Announces Results from ReDUX4 Trial with Losmapimod in Facioscapulohumeral Muscular Dystrophy (FSHD) Demonstrating Slowed Disease Progression and Improved Function. source
$EGRX +4.9% Eagle Pharmaceuticals Announces FDA Maintains Prioritization of ANDA for Vasopressin. source
Financial Updates
$ETNB +13.2% Presented at Raymond James Human Health Innovation Conference 6/23 on "Current Thinking in Nash". source
$ANVS +1.3% Annovis Bio CEO Selected as a Finalist in the 2021 PACT Enterprise Awards. source
Posted by FS